The B2B platform is designed to securely exchange active pharmaceutical ingredients (APIs) and additives between traders, buyers and sellers – all of which are required to meet predefined quality assurance requisites and financial criteria.
“Kemiex contributes to the digitalisation of pharma supply chains – as well as veterinary, human and animal nutrition industries – and specifically makes the activities of buying and selling APIs and additives safer and more convenient,” chief marketing officer Stefan Schmidinger told us.
“The platform connects companies to a global network that is compliant with latest regulations and quality controls,” he added.
Trade credit insurance – provided by strategic partner Atradius – is available for transactions 24/7.
The revenue model – under which sellers will pay less than 2% for every deal successfully closed on the platform – is based on successful transactions – there is no advertising or hidden fees, we were told.
Platform trading will officially launch later this year.
Schmidinger told us the site is now open for registration, adding: “Onboarding and demo presentation is a bespoke process for selected, reputable companies.”
In 2016, pharmaceutical consultancy firm Rephine told in-PharmaTechnologist it also hoped to launch an online API platform, but with a focus on good manufacturing practice (GMP) audits and supplier databases.
Earlier this year, the firm launched the database, which is designed to address the burden of ingredient supplier validation.